ImmunoGen, Inc. (IMGN) Q3 2022 Earnings Call Transcript

Nov. 04, 2022 1:22 PM ETImmunoGen, Inc. (IMGN)
SA Transcripts profile picture
SA Transcripts
133.94K Followers

ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET

Company Participants

Anabel Chan - Head, Investor Relations

Mark Enyedy - President, CEO & Director

Anna Berkenblit - SVP & Chief Medical Officer

Susan Altschuller - SVP & CFO

Conference Call Participants

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim Securities

Etzer Darout - BMO Capital Markets

Faisal Khurshid - SVB Securities

Andy Hsieh - William Blair & Company

Peter Lawson - Barclays Bank

Arthur He - H.C. Wainwright & Co.

Boris Peaker - Cowen and Company

Kelly Shi - Jefferies

Daniel Wolle - JPMorgan Chase & Co.

Operator

Good morning, and welcome to ImmunoGen's Third Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.

Anabel Chan

Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and third quarter 2022 financial results. This press release, a recording of this call and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com.

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, CFO. During today's call, we will review recent accomplishments for the business, our Q3 financial results and highlight upcoming anticipated events.

We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning. In the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.